19:00 , Dec 8, 2017 |  BC Week In Review  |  Clinical News

Tetra reports preliminary Phase I data for AD candidate BPN14770

Tetra Discovery Partners LLC (Grand Rapids, Mich.) reported preliminary data from a Phase I trial in 45 healthy elderly volunteers showing that twice-daily 10 and 20 mg oral doses of Alzheimer's disease candidate BPN14770 for...
08:00 , Jan 18, 2016 |  BC Week In Review  |  Clinical News

BPN14770: Phase I started

Tetra began a double-blind, placebo-controlled, U.S. Phase I trial to evaluate single ascending doses of oral BPN14770 in about 48 healthy volunteers. Tetra Discovery Partners LLC, Grand Rapids, Mich.   Product: BPN14770   Business: Neurology   Molecular...
01:33 , Dec 31, 2015 |  BC Extra  |  Clinical News

Tetra candidate backed by NIH's Blueprint enters clinic

Tetra Discovery Partners LLC (Grand Rapids, Mich.) began Phase I testing of BPN14770, the first candidate funded by NIH's Blueprint Neurotherapeutics Network (BPN) to reach the clinic. The negative allosteric modulator of phosphodiesterase-4D ( PDE-4D)...